Haemostatix

About:

Haemostatix has developed a new class of active clotting agent, or "haemostat" for the control of bleeding.

Website: http://www.haemostatix.com/home.html

Top Investors: Wellcome Trust, Albion Capital Group, Catapult Ventures, Spark Ventures, Nesta Ventures

Description:

Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation of clots. The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats. This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery, trauma and in leukaemic patients.